Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings Summary on May 17, 2018

May 17, 2018 - By Linda Ocallaghan

Big Money Sentiment decreased to 0.98 in Q4 2017. It has change of 0.31, from 2017Q3’s 1.29. The ratio dived due to Integra LifeSciences Holdings Corporation positioning: 20 sold and 70 reduced. 23 funds acquired positions and 65 increased positions. Investors holded 68.21 million in 2017Q3 but now own 70.22 million shares or 2.95% more.
Ameriprise has 418,067 shs. Eaton Vance has 0.02% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Burney has invested 0.02% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). California State Teachers Retirement invested in 0.01% or 100,307 shs. Vaughan Nelson Invest L P reported 576,100 shs. Moreover, Stoneridge Invest Prns Ltd Liability has 0.06% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART) for 7,507 shs. Susquehanna Int Group Limited Liability Partnership has 0% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Delta Asset Mgmt Tn stated it has 0% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Moreover, Manufacturers Life Insur The has 0% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Etrade Cap Mngmt Llc has 15,911 shs for 0.02% of their capital. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 3,806 shs. Victory Capital Management has invested 0.04% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). First Tru Ltd Partnership owns 0% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART) for 18,879 shs. Cibc Asset Incorporated accumulated 0% or 5,116 shs. Whittier Tru owns 3,344 shs for 0.01% of their capital.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings Coverage

A total of 9 analysts rate Integra Lifesciences (NASDAQ:IART) as follows: 3 “Buy”, 6 “Hold” and 0 “Sell”. Тherefore 33% are bullish. (NASDAQ:IART) has 10 ratings reports on May 17, 2018 according to StockzIntelligence. In Thursday, April 26 report JP Morgan maintained it with “Neutral” rating and $57 target. In Thursday, March 29 report Oppenheimer maintained the stock with “Buy” rating. On Tuesday, January 2 the company was downgraded by Bank of America. On Wednesday, April 25 the stock of Integra LifeSciences Holdings Corporation (NASDAQ:IART) earned “Buy” rating by Jefferies. On Wednesday, April 11 the stock of Integra LifeSciences Holdings Corporation (NASDAQ:IART) earned “Neutral” rating by JP Morgan. On Wednesday, February 28 the stock of Integra LifeSciences Holdings Corporation (NASDAQ:IART) has “Market Outperform” rating given by JMP Securities. In Wednesday, April 25 report Cantor Fitzgerald maintained it with “Hold” rating and $5200 target. On Tuesday, January 2 the stock of Integra LifeSciences Holdings Corporation (NASDAQ:IART) has “Market Perform” rating given by Raymond James. Listed here are Integra LifeSciences Holdings Corporation (NASDAQ:IART) PTs and latest ratings.

25/04/2018 Broker: Jefferies Rating: Buy New Target: $70.0000 Maintain
26/04/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $55 New Target: $57 Maintain
25/04/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $52.0000 Maintain
11/04/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $50 New Target: $55 Maintain
05/04/2018 Broker: BTIG Research Rating: Neutral New Target: $56 Initiates Coverage On
29/03/2018 Broker: Oppenheimer Rating: Buy New Target: $58.0000 Maintain
28/02/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $57 New Target: $60 Maintain
08/01/2018 Broker: Barclays Capital Rating: Hold New Target: $53.0
02/01/2018 Broker: Raymond James Old Rating: Outperform New Rating: Market Perform Old Target: $55 Downgrade
02/01/2018 Broker: Bank of America Old Rating: Buy New Rating: Neutral Downgrade

IART is hitting $63.85 during the last trading session, after increased 1.04%.Integra LifeSciences Holdings Corporation has 666,578 shares volume, 5.58% up from normal. IART is uptrending and has moved 29.35% since May 17, 2017. IART outperformed by 17.80% the S&P 500.

Integra LifeSciences Holdings Corporation develops, makes, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery.The company has $5.23 billion market cap. The firm operates through two divisions, Specialty Surgical Solutions; and Orthopedics and Tissue Technologies.77.87 is the P/E ratio. It offers neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.

A couple more Integra LifeSciences Holdings Corporation (NASDAQ:IART) news were announced by: Globenewswire.com which released on May 17, 2018 “Analysis: Positioning to Benefit within Webster Financial, Integra LifeSciences, OSI, Tivity Health, LCI Industries, and …”, also Globenewswire.com on April 25, 2018 announced “Integra LifeSciences Reports First Quarter 2018 Financial Results”, the next Globenewswire.com is “Integra LifeSciences Announces Proposed Public Offering of Common Stock” on May 09, 2018. Globenewswire.com has article titled “Integra LifeSciences Prices Public Offering of Common Stock”.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.